iCAD Inc. (ICAD) develops and markets oncology solutions which enhance patient care at all levels of the cancer care cycle. For investors looking at the company's fundamentals over the past few years, ICAD appears to be moving in the wrong direction. Revenue has been stagnant and profitability has been elusive. In many ways, ICAD reminds us of CalAmp Corp. (CAMP) 18 months ago. Beset with a legacy business on the decline, CalAmp embarked on a series of new product releases in its wireless business which sparked a renaissance for both its top line and bottom line. As CAMP's business turned around, investors took notice, bidding up the shares three-fold since the summer of 2009.
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: